News & Resources

ArchPharm 2023 Aug;356(8):e2300101
ABDEL-TAWAB M. ET AL: An exploratory study on the effect of mechanical stress on particle formation in monoclonal antibody infusions

JHEP Reports. 2023 Feb; 5(2): 100603
SACHERL J. ET AL: Efficient stabilization of therapeutic hepatitis B vaccine components by amino-acid formulation maintains its potential to break immune tolerance

”A Specialist in Bioinformatics based Stabilization of All kinds of Biological Molecules". ISSN 2831-8331

S. Smith,” Liquid formulation bolstered by AI". ISSN 2644-2787

F. Thomas,” Pharmaceutical Technology Europe 33 (4) 2021.

pharmtech.com/view/focusing-on-accelerated-formulation-strategies

Rentschler Biopharma SE/ Leukocare AG: Contract Pharma_54-58 Advertorial 1020
BHONSLE-DEENG L. and PETROPOULOS K.: Advanced Formulation Development by Design in the Context of Holistic Drug Production

Journal of Pharmaceutical Sciences 109 (2020) 818-829
REINAUER E. ET AL: Algorithm-Based Liquid Formulation Development Including a DoE Concept Predicts Long-Term Viral Vector Stability

European Biopharmaceutical Review January 2019, pages 28-36. © Samedan Ltd
ALTRICHTER J. ET AL: Exploring Amino Acid- Based and Stable Spray- Dried Vaccinations

Rentschler Biopharma SE / LEUKOCARE AG/ Informa Pharma Intelligence
"2018 Survey- Formulation in the Drug Product Development Process": 2018 Survey ‘Formulation in the Drug Product Development Process’, based on research from Informa Pharma Intelligence

European Biotechnology | Autumn Edition | Vol. 17 | 2018
"Formulation matters": Interview with LEUKOCARE´s CEO Michael Scholl about the impact of formulation on drug product performance.

Biotechnol. J. 2018, 13, 1700523
SCHOLZ M. ET AL.:Amino acid-based advanced liquid formulation development for highly concentrated therapeutic antibodies balances physical and chemical stability and low viscosity

2014 December, PLoS ONE 9(12): e115940. doi:10.1371/journal.pone.
WINDOLF C.D. ET AL.:Lysostaphin-Coated Titan-Implants Preventing Localized Osteitis by Staphyloccus aureus in a Mouse Model

2014 July; Vol. 10, Issue 10, Meeting Report
DERWAND R.: Annual World Vaccine Congress 2014: A re-evaluation of the value proposition for increasing vaccine thermostability

2014 April; Vol. 32, Issue 19
SCHERLIESS R. ET AL.: Induction of protective immunity against H1N1 influenza A(H1N1)pdm09 with spray-dried and electron-beam sterilised vaccines in non-human primates

2012 September; Vol. 15, Number 9
TSCHELIESSNIG R. ET AL.: Nano-coating protects biofunctional materials

2012 March; Vol. 7, Issue 8
SCHOLZ M. and LÜKING A.: A protein-stabilizing technology for enhanced antibody stability and antibody-binding profiles in a microchip array

2011 Mar; 216(3): 334-42
PAUNEL-GOERGUELUE A. ET AL.: Stimulation of Fas signaling down-regulates activity of neutrophils from major trauma patients with SIRS

2010 Apr; 20(7): 18
LÖGTERS T. ET AL.: Extracorporeal immune therapy with immobilized agionistic anti-Fas antibodies leads to transient reduction of circulating neutrophil numbers and limits tissue damage after hemorrhagic shock/resuscitation in a porcine model

2009 Nov; 15: 183(10): 6198-6206
PAUNEL-GOERGUELUE A. ET AL.: McI-1-mediated impairment of the intrinsic apoptosis pathway in circulating neutrophils from critically ill patients can be overcome by Fas stimulation

2009-nov-198(4)-211-9-lögters-t-et-al-the-clinical-value-of-extracellular-traps

2009 Jul; 32(1): 29-34
LÖGTERS T. ET AL.: Increased plasma kynurenine values and kynurenine: tryptophan ratios after major trauma are early indicators for the development of sepsis

2009 Nov; 27(11): 1401-7
LÖGTERS T. ET AL.: Diagnostic accuracy of neutrophil-derived circulating free DNA (cf-DNA/NETs) for septic arthritis

2008 Oct; 30 (4): 352-8
MARGRAF S. ET AL.: Neutrophil-derived circulating free DNA (cf-DNA/NETs): a potential prognostic marker for posttraumatic development of inflammatory second hit and sepsi

2007 Oct; 4:21
ABDEL-RAHMAN U. ET AL.: Inhibition of neutrophil activity improves cardiac function after cardiopulmonary bypass

2007 May; 27(3): 401-16
SCHOLZ M. ET AL.: Neutrophils and the blood-brain barrier dysfunction after trauma

2005 May; 25(3): 331-42
SCHOLZ M. ET AL.: Fas/FasL interaction: a novel immune therapy approach with immobilized biologicals

2005 Apr 8; 329(2): 616-23
SCHULLER AM. ET AL.: Degradation of microvascular brain endothelial cell beta-catenin after co-culture with activated neutrophils from patients undergoing cardiac surgery with prolonged cardiopulmonary bypass

2005 Mar-Apr; 51(2): 144-7
SCHOLZ M. ET AL.: First efficacy and safety results with the antibody containing leukocyte inhibition module in cardiac surgery patients with neutrophil hyperactivity

2004 Jun; 127(6): 1735-42
SCHOLZ M. ET AL.: In vivo inhibition of neutrophil activity by a FAS (CD95) stimulating module: arterial in-line application in a porcine cardiac surgery model

2004 Jan; 19(1): 11-6
MORENO JB. ET AL.: Inhibition of neutrophil activity in cardiac surgery with cardiopulmonary bypass: a novel strategy with the leukocyte inhibition module